Zydus Lifesciences | Page 3 | Business Upturn

Latest Articles

Zydus Lifesciences’ Ankleshwar API unit clears USFDA inspection with zero observations

Corporates · Mar 15, 2025

By Aditya Bhagchandani

blank

Zydus Lifesciences to acquire 85.6% stake in Amplitude Surgical SA for Rs 2,442 crore

Corporates · Mar 11, 2025

blank

Zydus Lifesciences secures USFDA approval for Dasatinib Tablets

Corporates · Mar 5, 2025

blank

Zydus Lifesciences launches ANVIMO for transplant patients

Corporates · Mar 5, 2025

blank

Zydus Lifesciences announces U.S. FDA priority review for CUTX-101, a potential first-in-class treatment for Menkes disease

Corporates · Jan 7, 2025

By Aditya Bhagchandani

blank

Zydus Lifesciences receives USFDA approval for Lidocaine and Prilocaine Cream USP

Corporates · Dec 19, 2024

blank

Zydus Lifesciences’s market cap gains Rs 1,363 crore as stock surges 1.43%

Stock Market · Nov 13, 2024

By Aditya Bhagchandani

blank

Zydus Lifesciences stock drops 2% on Q2 results

Stock Market · Nov 12, 2024

blank

Zydus Lifesciences Q2 FY25: Revenue up 20% YoY to Rs 5237 crore, Net Profit up 13.7% YoY

Corporates · Nov 12, 2024

By Aditya Bhagchandani

blank

Zydus Lifesciences receives WHO approval for ZyVac® TCV, making it eligible for UN procurement

Stock Market · Oct 23, 2024

By Aditya Bhagchandani

Zydus Lifesciences

Zydus Lifesciences gets USFDA approval to manufacture Fludrocortisone Acetate tablets

Corporates · Oct 17, 2024

blank

Zydus Lifesciences shares decline nearly 3% after Exelixis wins patent ruling over MSN Labs’ Cabometyx copies

Stock Market · Oct 16, 2024

By Aditya Bhagchandani

blank

Zydus Lifesciences gets tentative approval from USFDA for Enzalutamide Tablets, 40 mg and 80 mg

Corporates · Oct 2, 2024

blank

Zydus receives USFDA approval for Enzalutamide Capsules

Corporates · Sep 28, 2024

By Aditya Bhagchandani

blank

BofA Securities cuts target prices for Zydus Life and Lupin shares amid Mirabegron uncertainty

Stock Market · Sep 20, 2024

Showing 45 of 62 articles